AEON Biopharma, Inc.

Company snapshot

• Business: Biopharmaceutical company developing ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) for therapeutic indications in the United States and select international markets.
• Formation: Completed a business combination with Priveterra Acquisition Corp. on July 21, 2023; trades on NYSE American as AEON.
• Headquarters: Irvine, California. Principal executive office: 5 Park Plaza, Suite 1750, Irvine, CA 92614.
• Employees: Eight (all full-time in the U.S.) as of December 31, 2025.

Strategy and rights

• Regulatory pathway: Pursuing approval in the U.S. under the 351(k) biosimilar pathway (Section 351(k) BLA) for ABP-450, with the objective of achieving full-label therapeutic indications aligned with Botox®’s approved therapeutic uses.
• Territory rights: Exclusive development and commercialization rights for ABP-450 in the U.S., Canada, the European Union, the United Kingdom, and certain other international territories.
• Market focus: Therapeutic botulinum toxin market (excluding cosmetic uses), which the company estimates at approximately $3.3 billion in 2025 with an ~8% CAGR.

ABP-450 program and regulatory status

• Product: ABP-450 is the same 900 kDa botulinum toxin complex used in Jeuveau® (Evolus) and Nabota® (Daewoong), with the same active 150 kDa botulinum toxin component.
• Analytical development: Conducting an analytical similarity program covering primary structure, functional assays, and comparability work. FDA feedback from a BPD Type 2a meeting (January 2026) acknowledged challenges and accepted the proposed analytical approach; the company plans to complete most analytical work in 2026. A BPD Type 2b meeting is planned in 2026 to discuss next steps.
• Clinical approach: Previously conducted Phase 2 migraine studies (now discontinued). Current development strategy centers on analytical similarity and, if needed, targeted clinical studies to support a 351(k) BLA for therapeutic indications.
• Prior data: ABP-450 has prior nonclinical and some human data, including Phase 2 cervical dystonia and migraine data from programs associated with the 900 kDa complex.
• Regulatory framework: Intends to demonstrate high similarity to a licensed reference product with the same mechanism of action, route of administration, dosage form, and strength; extrapolation to multiple indications will depend on FDA determination.

Manufacturing and supply

• Manufacturer: Daewoong Pharmaceutical Co., Ltd. is the exclusive manufacturer and holds the manufacturing process IP. Daewoong supplies the ABP-450 drug substance (fermentation and purification) from its facility in Korea.
• License model: AEON holds an exclusive license to import, distribute, market, develop, and commercialize ABP-450 for therapeutic indications in the covered territories under a Daewoong-supplied model.
• Contract terms and risks: The Daewoong agreement provides term-based exclusivity, supply obligations, and termination rights. If Daewoong terminates or exclusivity is lost, AEON could face material delays and challenges in securing alternative supply and obtaining new regulatory approvals.
• Term and termination: Initial term through the later of five years after regulatory approval or December 20, 2029, with automatic three-year renewals. Agreements may be terminated for uncured breach; in some cases, Daewoong can acquire AEON’s IP for $1 if certain termination events occur.
• Supply considerations: Manufacturing scale-up, cGMP compliance, and batch consistency are central to supply capability; Daewoong’s facility and QA controls are a key element of AEON’s ability to supply ABP-450.

Intellectual property

• IP strategy: Mix of patents, trade secrets, and know-how. Daewoong holds a U.S. patent related to ABP-450 manufacturing.
• AEON patents: One issued U.S. patent (U.S. Patent No. 11,826,405) related to a migraine injection paradigm; multiple patent applications filed without broad issued composition claims covering ABP-450 to date.
• Licensing dependence: AEON depends on Daewoong licenses and may pursue additional licenses as needed. Failures to maintain or enforce IP or license rights could threaten development and commercialization.
• Trademarks: AEON licenses the Nabota® trademark from Daewoong for ABP-450 and may pursue alternative branding in the future.

Market and competition

• Key competitors: Botox® (AbbVie), Dysport® (Ipsen), Xeomin® (Merz), and daxibotulinumtoxinA (Revance) in development or early commercialization.
• Regulatory pathway implications: A successful 351(k) biosimilar pathway could enable extrapolation to Botox® indications, but extrapolation is subject to FDA determination and may be limited for some indications.
• Payer and international dynamics: Reimbursement, ASP, 340B, IRA, and country-specific regulatory and pricing environments will influence adoption and pricing after approval.

Financial position

• Revenue and profitability: No product revenue to date; AEON has never been profitable.
• Accumulated deficit: $470.8 million as of December 31, 2025.
• Cash: $3.0 million in cash and cash equivalents as of December 31, 2025.
• Liquidity outlook: The company disclosed substantial doubt about ongoing operations and expects current cash and funds from a January 2026 closing to fund operations through the third quarter of 2026.
• Capital history: Since 2019 AEON has raised approximately $203 million, including PIPE proceeds totaling $6.0 million (with $1.8 million received at a November 2025 first closing and $4.2 million at a January 2026 second closing).
• Financing needs: Additional capital will be required to fund development, regulatory activities, and potential commercialization. Future funding could dilute existing stockholders if raised through equity.

Public company status and governance

• Listing and compliance: Public company listed on NYSE American; subject to SEC reporting, Sarbanes-Oxley, and other corporate governance requirements.
• Legal exposures: The company has potential liabilities and litigation exposure related to licensing, IP, and corporate matters, including prior and ongoing litigation with Medytox and other parties, as well as SPAC-related securities litigation risk.

Location and operations

• Principal office: Irvine, California. Lease expanded in March 2024 to extend a prior 8,000 sq ft space for an additional five years.

Key numeric details

• Employees: 8 (as of 12/31/2025)
• Cash and cash equivalents: $3.0 million (as of 12/31/2025)
• Accumulated deficit: $470.8 million (as of 12/31/2025)
• Manufacturing: ABP-450 supplied exclusively by Daewoong from a Korea facility designed to cGMP standards; Daewoong has prior regulatory-inspection history relevant to FDA and EMA.
• 2026 funding events: January 2026 second closing contributed $4.2 million.
• PIPE history: Total raised since 2019 ~ $203 million.

Summary

AEON Biopharma, Inc. is a SPAC-derived biopharma company focused on developing ABP-450 as a Botox® biosimilar for therapeutic indications. The company is pursuing a 351(k) BLA in the U.S., holds exclusive rights in several major territories, and relies on Daewoong for manufacturing and key IP. AEON has no product revenue, a limited cash runway as of year-end 2025, and ongoing financing requirements to advance development, regulatory filings, and potential commercialization. Upcoming regulatory interactions in 2026 include a planned BPD Type 2b meeting following a January 2026 Type 2a discussion.